-+ 0.00%
-+ 0.00%
-+ 0.00%

YKYY036 injection, a subsidiary of Yuekang Pharmaceutical (688658.SH), was approved for clinical trials by NMPA and FDA

Zhitongcaijing·10/13/2026 12:09:22
Listen to the news

Zhitong Finance App News, Yuekang Pharmaceutical (688658.SH) issued an announcement. The company's subsidiaries Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Yuekang Pharmaceutical Group Hangzhou Tianlong Pharmaceutical Co., Ltd. have recently obtained the approval and issuance of the “Drug Clinical Trial Approval Notice” from the National Drug Administration (“NMPA”) to agree that YKYY036 injections are used for obesity or overweight. Meanwhile, Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. recently received a letter from the US Food and Drug Administration (“FDA”) to agree to the application for clinical trials of YKYY036 injections for overweight or obesity (Study May Proceed Letter, IND number: 183361).